CN115151278B - 用于核酸疗法的靶向肿瘤的多肽纳米颗粒递送系统 - Google Patents
用于核酸疗法的靶向肿瘤的多肽纳米颗粒递送系统Info
- Publication number
- CN115151278B CN115151278B CN202080084185.2A CN202080084185A CN115151278B CN 115151278 B CN115151278 B CN 115151278B CN 202080084185 A CN202080084185 A CN 202080084185A CN 115151278 B CN115151278 B CN 115151278B
- Authority
- CN
- China
- Prior art keywords
- peptide
- nucleic acid
- sirna
- hkp
- hkc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910760P | 2019-10-04 | 2019-10-04 | |
| US62/910,760 | 2019-10-04 | ||
| US201962915450P | 2019-10-15 | 2019-10-15 | |
| US62/915,450 | 2019-10-15 | ||
| PCT/US2020/054251 WO2021067930A1 (en) | 2019-10-04 | 2020-10-05 | Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115151278A CN115151278A (zh) | 2022-10-04 |
| CN115151278B true CN115151278B (zh) | 2025-08-22 |
Family
ID=75337467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080084185.2A Active CN115151278B (zh) | 2019-10-04 | 2020-10-05 | 用于核酸疗法的靶向肿瘤的多肽纳米颗粒递送系统 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220331441A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4037716A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7644105B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220110174A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115151278B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020357078A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022006473A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156823A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291916A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067930A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202204734B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7512207B2 (ja) * | 2018-05-24 | 2024-07-08 | サーナオミクス インコーポレイテッド | 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法 |
| CN118613484A (zh) * | 2021-12-30 | 2024-09-06 | 拜奥迪斯私人有限公司 | 抗叶酸剂接头-药物和抗体-药物缀合物 |
| CN120158469A (zh) * | 2025-05-19 | 2025-06-17 | 内蒙古大学 | 一种灌胃递送靶向编辑甲烷八叠球菌的牛甲烷减排方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080171025A1 (en) * | 2004-11-17 | 2008-07-17 | Archibald Mixson | Highly Branched Hk Peptides as Effective Carriers of Sirna |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10501963A (ja) * | 1994-04-15 | 1998-02-24 | ターゲテッド ジェネティクス コーポレイション | 遺伝子送達融合タンパク質 |
| EP1817416A2 (en) * | 2004-11-05 | 2007-08-15 | Intradigm Corporation | Compositions for treating respiratory viral infections and their use |
| ES2545963T3 (es) * | 2007-11-06 | 2015-09-17 | Sirnaomics, Inc. | Terapéutica con ARNi multidirigidos para la cicatrización de heridas de la piel sin cicatriz |
| CN102316858A (zh) * | 2008-02-26 | 2012-01-11 | 阿帕玛生物科技公司 | 修饰过的可调的纳米粒子用于传递治疗,诊断,实验化合物及相关成分用于治疗用药 |
| WO2010078517A2 (en) | 2008-12-31 | 2010-07-08 | Sirnaomics, Inc. | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer |
| WO2011011631A2 (en) * | 2009-07-22 | 2011-01-27 | Samuel Zalipsky | Nucleic acid delivery vehicles |
| US11058779B2 (en) * | 2015-09-08 | 2021-07-13 | Sirnaomics, Inc. | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection |
| CN107793388B (zh) * | 2016-10-14 | 2021-06-11 | 长沙天赐生物医药科技有限公司 | 平板霉素类似物及其制备方法和应用 |
| EP3532071A4 (en) * | 2016-10-30 | 2020-09-02 | Sirnaomics, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE TO ACTIVATE HUMAN FIBROBLAST AND MYOFIBROBLAST APOPTOSIS |
| JP7512207B2 (ja) | 2018-05-24 | 2024-07-08 | サーナオミクス インコーポレイテッド | 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法 |
| US20210180089A1 (en) * | 2018-08-14 | 2021-06-17 | Loxegen Holdings Pty Ltd | Nanoparticles for transfection |
| WO2021061437A1 (en) | 2019-09-12 | 2021-04-01 | Sirnaomics, Inc. | CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER |
-
2020
- 2020-10-05 KR KR1020227014303A patent/KR20220110174A/ko not_active Ceased
- 2020-10-05 IL IL291916A patent/IL291916A/en unknown
- 2020-10-05 JP JP2022520803A patent/JP7644105B2/ja active Active
- 2020-10-05 CN CN202080084185.2A patent/CN115151278B/zh active Active
- 2020-10-05 CA CA3156823A patent/CA3156823A1/en active Pending
- 2020-10-05 WO PCT/US2020/054251 patent/WO2021067930A1/en not_active Ceased
- 2020-10-05 EP EP20872228.0A patent/EP4037716A4/en not_active Withdrawn
- 2020-10-05 BR BR112022006473A patent/BR112022006473A2/pt not_active IP Right Cessation
- 2020-10-05 AU AU2020357078A patent/AU2020357078A1/en not_active Abandoned
-
2022
- 2022-04-04 US US17/713,037 patent/US20220331441A1/en active Pending
- 2022-04-28 ZA ZA2022/04734A patent/ZA202204734B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080171025A1 (en) * | 2004-11-17 | 2008-07-17 | Archibald Mixson | Highly Branched Hk Peptides as Effective Carriers of Sirna |
Non-Patent Citations (2)
| Title |
|---|
| Selective Modification of HK Peptides Enhances siRNA Silencing of Tumor Targets In Vivo;Szu-Ting Chou et al.;Cancer Gene Ther.;20111031;第18卷(第10期);摘要,Polymers,Gel Retardation Assay, HK:siRNA nanoparticle preparation, Optimization of HK-siRNA Nanoplexes * |
| Szu-Ting Chou et al. .Selective Modification of HK Peptides Enhances siRNA Silencing of Tumor Targets In Vivo.Cancer Gene Ther..2011,第18卷(第10期),摘要,Polymers,Gel Retardation Assay,HK:siRNA nanoparticle preparation,Optimization of HK-siRNA Nanoplexes. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022550901A (ja) | 2022-12-05 |
| BR112022006473A2 (pt) | 2022-07-05 |
| WO2021067930A1 (en) | 2021-04-08 |
| EP4037716A4 (en) | 2023-05-03 |
| US20220331441A1 (en) | 2022-10-20 |
| CA3156823A1 (en) | 2021-04-08 |
| AU2020357078A1 (en) | 2022-05-26 |
| ZA202204734B (en) | 2024-09-25 |
| EP4037716A1 (en) | 2022-08-10 |
| IL291916A (en) | 2022-06-01 |
| JP7644105B2 (ja) | 2025-03-11 |
| KR20220110174A (ko) | 2022-08-05 |
| CN115151278A (zh) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101617790B1 (ko) | 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물 | |
| JP3950472B2 (ja) | 自己構築ポリヌクレオチド送達システム | |
| Gooding et al. | Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis | |
| EP2007432B1 (en) | Biodegradable cationic polymers | |
| CN101808668B (zh) | 药物内包活性靶向型高分子微团、医药组合物 | |
| US8592385B2 (en) | Polymer micelle complex including nucleic acid | |
| Tang et al. | Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT | |
| CN102892420A (zh) | 用于递送寡核苷酸的新型单一化学实体和方法 | |
| JP2010526091A (ja) | 癌の処置のための生物学的な標的基の改変 | |
| CN102027043A (zh) | 生物可降解的交联支链聚(亚烷基亚胺) | |
| JP2010526091A5 (cg-RX-API-DMAC7.html) | ||
| US20220331441A1 (en) | Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics | |
| WO1998046274A2 (en) | Cationic polymers for nucleic acid transfection | |
| CN105377302B (zh) | 聚合物胶束医药组合物 | |
| CN114392358A (zh) | 一种肿瘤靶向的核酸适体药物偶连物 | |
| CN103665169B (zh) | 三功能肽修饰的基因载体及其制备方法与应用 | |
| Zhang et al. | A zwitterionic polymer-inspired material mediated efficient CRISPR-Cas9 gene editing | |
| JP2022550901A5 (cg-RX-API-DMAC7.html) | ||
| EP4424701A1 (en) | Cyclic polypeptide carrier for efficient delivery of nucleic acid, and variants thereof | |
| US11351263B2 (en) | Polyplex delivery system for proteins, nucleic acids and protein/nucleic acid complexes | |
| KR102013908B1 (ko) | 변형 지방산 인지질 및 양이온성 폴리펩티드 컨쥬게이트를 포함하는 핵산 전달용 조성물 | |
| JP2003503569A (ja) | 核酸を細胞に輸送するためのコポリマー | |
| EP4578869A1 (en) | Branched polypeptide vector for effectively delivering nucleic acids and variant thereof | |
| US20240336655A1 (en) | Amphiphilic peptides for nucleic acid and protein delivery | |
| Kos et al. | Gene transfer with sequence-defined oligo (ethanamino) amides bioreducibly attached to a propylenimine dendrimer core |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |